Concomitant twice‐a‐day radiotherapy and chemotherapy in unresectable head and neck cancer patients: A long‐term quality of life analysis

Abstract

The interest of twice-a-day radiotherapy with concomitant chemotherapy is to increase total radiotherapy equivalent dose without increasing late toxicity and also to improve locoregional control, survival, and long-term QoL/effectiveness ratio. Best supportive care is recommended to obtain both good QoL and cancer control in a long-term follow-up.